{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:49:18Z","timestamp":1793828958250,"version":"4.6.1"},"reference-count":53,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Swedish State Support for Clinical Research","award":["ALFGBG-720931"],"award-info":[{"award-number":["ALFGBG-720931"]}]},{"DOI":"10.13039\/100010269","name":"Wellcome","doi-asserted-by":"publisher","award":["103838"],"award-info":[{"award-number":["103838"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019544","name":"Cambridge Centre for Parkinson-Plus","doi-asserted-by":"crossref","award":["No grant\/award number"],"award-info":[{"award-number":["No grant\/award number"]}],"id":[{"id":"10.13039\/501100019544","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["681712"],"award-info":[{"award-number":["681712"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100017510","name":"UK Dementia Research Institute","doi-asserted-by":"publisher","award":["No grant\/award number"],"award-info":[{"award-number":["No grant\/award number"]}],"id":[{"id":"10.13039\/501100017510","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","award":["201809-2016862"],"award-info":[{"award-number":["201809-2016862"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["Biomedical Research Centre at Cambridge University"],"award-info":[{"award-number":["Biomedical Research Centre at Cambridge University"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["Newcastle Biomedical Research Centre (No grant\/awa"],"award-info":[{"award-number":["Newcastle Biomedical Research Centre (No grant\/awa"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>This longitudinal study compared emerging plasma biomarkers for neurodegenerative disease between controls, patients with Alzheimer\u2019s disease (AD), Lewy body dementia (LBD), frontotemporal dementia (FTD) and progressive supranuclear palsy (PSP).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Plasma phosphorylated tau at threonine-181 (p-tau181), amyloid beta (\u0391\u03b2)42, A\u03b240, neurofilament light (NfL) and glial fibrillar acidic protein (GFAP) were measured using highly sensitive single molecule immunoassays (Simoa) in a multicentre cohort of 300 participants (controls=73, amyloid positive mild cognitive impairment (MCI+) and AD dementia=63, LBD=117, FTD=28, PSP=19). LBD participants had known positron emission tomography (PET)-A\u03b2 status.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>P-tau181 was elevated in MCI+AD compared with all other groups. A\u03b242\/40 was lower in MCI+AD compared with controls and FTD. NfL was elevated in all dementias compared with controls while GFAP was elevated in MCI+AD\u2009and LBD. Plasma biomarkers could classify between MCI+AD\u2009and controls, FTD and PSP with high accuracy but showed limited ability in differentiating MCI+AD from LBD. No differences were detected in the levels of plasma biomarkers when comparing PET-A\u03b2 positive and negative LBD. P-tau181, NfL and GFAP were associated with baseline and longitudinal cognitive decline in a disease specific pattern.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This large study shows the role of plasma biomarkers in differentiating patients with different dementias, and at monitoring longitudinal change. We confirm that p-tau181 is elevated in MCI+AD, versus controls, FTD and PSP, but is less accurate in the classification between MCI+AD\u2009and LBD or detecting amyloid brain pathology in LBD. NfL was elevated in all dementia groups, while GFAP was elevated in MCI+AD\u2009and LBD.<\/jats:p><\/jats:sec>","DOI":"10.1136\/jnnp-2021-327788","type":"journal-article","created":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T18:25:55Z","timestamp":1643135155000},"page":"651-658","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":192,"title":["Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer\u2019s disease, frontotemporal dementia and progressive supranuclear palsy"],"prefix":"10.1136","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3052-3879","authenticated-orcid":false,"given":"Leonidas","family":"Chouliaras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8923-9656","authenticated-orcid":false,"given":"Maura","family":"Malpetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Donaghy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elijah","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Savulich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A","family":"Prats-Sedano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda J","family":"Heslegrave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-4354","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7216-8679","authenticated-orcid":false,"given":"James Benedict","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Tiernan","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,1,25]]},"reference":[{"key":"2023052906053242000_93.6.651.1","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","article-title":"Biomarkers for neurodegenerative diseases","volume":"27","author":"Hansson","year":"2021","journal-title":"Nat Med"},{"key":"2023052906053242000_93.6.651.2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-326603"},{"key":"2023052906053242000_93.6.651.3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/alz.12068","article-title":"2020 Alzheimer\u2019s disease facts and figures","volume":"16","year":"2020","journal-title":"Alzheimer's &amp; Dementia"},{"key":"2023052906053242000_93.6.651.4","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-020-02195-x"},{"key":"2023052906053242000_93.6.651.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30071-5"},{"key":"2023052906053242000_93.6.651.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0755-1"},{"key":"2023052906053242000_93.6.651.7","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","article-title":"Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures","volume":"27","author":"Palmqvist","year":"2021","journal-title":"Nat Med"},{"key":"2023052906053242000_93.6.651.8","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","article-title":"Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology","volume":"141","author":"Ashton","year":"2021","journal-title":"Acta Neuropathol"},{"key":"2023052906053242000_93.6.651.9","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma Phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"key":"2023052906053242000_93.6.651.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0762-2"},{"key":"2023052906053242000_93.6.651.11","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa286"},{"key":"2023052906053242000_93.6.651.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-020-00923-z"},{"key":"2023052906053242000_93.6.651.13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13195-021-00802-x","article-title":"Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer\u2019s disease","volume":"13","author":"Tissot","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"2023052906053242000_93.6.651.14","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1093\/brain\/awab163","article-title":"Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects","volume":"144","author":"Pereira","year":"2021","journal-title":"Brain"},{"key":"2023052906053242000_93.6.651.15","doi-asserted-by":"publisher","DOI":"10.1038\/nature25456"},{"key":"2023052906053242000_93.6.651.16","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jamaneurol.2019.1632","article-title":"Performance of fully automated plasma assays as screening tests for Alzheimer disease-related \u03b2-amyloid status","volume":"76","author":"Palmqvist","year":"2019","journal-title":"JAMA Neurol"},{"key":"2023052906053242000_93.6.651.17","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","article-title":"Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis","volume":"76","author":"Bridel","year":"2019","journal-title":"JAMA Neurol"},{"key":"2023052906053242000_93.6.651.18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23620-z"},{"key":"2023052906053242000_93.6.651.19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-020-01137-1","article-title":"Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer\u2019s disease","volume":"11","author":"Chatterjee","year":"2021","journal-title":"Transl Psychiatry"},{"key":"2023052906053242000_93.6.651.20","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jalz.2019.09.004","article-title":"Plasma biomarkers of astrocytic and neuronal dysfunction in early- and late-onset Alzheimer's disease","volume":"16","author":"Elahi","year":"2020","journal-title":"Alzheimers Dement"},{"key":"2023052906053242000_93.6.651.21","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00804-9"},{"key":"2023052906053242000_93.6.651.22","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-018-0356-0"},{"key":"2023052906053242000_93.6.651.23","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/mds.27403","article-title":"Clinical and imaging correlates of amyloid deposition in dementia with Lewy bodies","volume":"33","author":"Donaghy","year":"2018","journal-title":"Mov Disord"},{"key":"2023052906053242000_93.6.651.24","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/mds.28370","article-title":"Plasma phospho-tau identifies Alzheimer's Co-Pathology in patients with Lewy body disease","volume":"36","author":"Hall","year":"2021","journal-title":"Mov Disord"},{"key":"2023052906053242000_93.6.651.25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013187"},{"key":"2023052906053242000_93.6.651.26","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.parkreldis.2019.01.024","article-title":"123 I-MIBG scintigraphy utility and cut-off value in a clinically representative dementia cohort","volume":"62","author":"Kane","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"key":"2023052906053242000_93.6.651.27","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/gps.5483","article-title":"The revised Addenbrooke's cognitive examination can facilitate differentiation of dementia with Lewy bodies from Alzheimer's disease","volume":"36","author":"Prats-Sedano","year":"2021","journal-title":"Int J Geriatr Psychiatry"},{"key":"2023052906053242000_93.6.651.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2016.08.005"},{"key":"2023052906053242000_93.6.651.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.005"},{"key":"2023052906053242000_93.6.651.30","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"key":"2023052906053242000_93.6.651.31","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21507"},{"key":"2023052906053242000_93.6.651.32","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awr179"},{"key":"2023052906053242000_93.6.651.33","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31821103e6"},{"key":"2023052906053242000_93.6.651.34","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.1.1"},{"key":"2023052906053242000_93.6.651.35","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26987"},{"key":"2023052906053242000_93.6.651.36","doi-asserted-by":"publisher","DOI":"10.1002\/gps.1610"},{"key":"2023052906053242000_93.6.651.37","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2012-303618"},{"key":"2023052906053242000_93.6.651.38","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-325549"},{"key":"2023052906053242000_93.6.651.39","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41582-020-0348-0","article-title":"An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders","volume":"16","author":"Ashton","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"2023052906053242000_93.6.651.40","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.jalz.2018.06.3053","article-title":"Association of cerebrospinal fluid \u03b1-synuclein with total and phospho-tau 181 protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers","volume":"14","author":"Vergallo","year":"2018","journal-title":"Alzheimers Dement"},{"key":"2023052906053242000_93.6.651.41","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/jnc.13399","article-title":"Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration","volume":"136","author":"Ishiki","year":"2016","journal-title":"J Neurochem"},{"key":"2023052906053242000_93.6.651.42","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-180325"},{"key":"2023052906053242000_93.6.651.43","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.parkreldis.2015.10.009","article-title":"Neuroinflammation in Lewy body dementia","volume":"21","author":"Surendranathan","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"key":"2023052906053242000_93.6.651.44","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/brain\/awy265","article-title":"Early microglial activation and peripheral inflammation in dementia with Lewy bodies","volume":"141","author":"Surendranathan","year":"2018","journal-title":"Brain"},{"key":"2023052906053242000_93.6.651.45","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-323698"},{"key":"2023052906053242000_93.6.651.46","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-326487"},{"key":"2023052906053242000_93.6.651.47","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-321954"},{"key":"2023052906053242000_93.6.651.48","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23746-0","article-title":"Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations","volume":"12","author":"Cullen","year":"2021","journal-title":"Nat Commun"},{"key":"2023052906053242000_93.6.651.49","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13195-021-00864-x","article-title":"Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer's disease","volume":"13","author":"Xiao","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"2023052906053242000_93.6.651.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2007.01.045"},{"key":"2023052906053242000_93.6.651.51","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000271090.28148.24"},{"key":"2023052906053242000_93.6.651.52","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-021-00430-x","article-title":"Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics","volume":"16","author":"Zetterberg","year":"2021","journal-title":"Mol Neurodegener"},{"key":"2023052906053242000_93.6.651.53","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3854"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2021-327788","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T13:08:22Z","timestamp":1685365702000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2021-327788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,25]]},"references-count":53,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,5,27]]},"published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1136\/jnnp-2021-327788"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2021-327788","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,25]]}}}